New drug combo aims to outsmart lung cancer that resists immunotherapy
NCT ID NCT07692048
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This trial tests a combination of two drugs—tislelizumab and SYS6010—in people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after immunotherapy. Tislelizumab is an approved immunotherapy, and SYS6010 is an experimental drug that targets EGFR on cancer cells to deliver a toxin. The study aims to see if the combination is safe and whether it can shrink tumors or slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab plus SYS6010
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy.
- What could go wrong
- This is an early-phase trial with only 21 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
Chengdu, Please Select, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?
- New drug combo aims to shrink tough lung tumors
- Blood test may let cancer patients take safe breaks from immunotherapy
- New targeted pill aims to shrink lung tumors in patients with common gene mutation
- Lung cancer drug interaction study aims to uncover safe dosing
- New PET scan could predict who benefits from targeted lung cancer therapy